ArticleMolecular pharmacology2018
Activation of Constitutive Androstane Receptor Ameliorates Renal Ischemia-Reperfusion-Induced Kidney and Liver Injury.
Abstract read
In one paragraph
Article in Molecular pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- ER stress-mediated impairment of hepatic lipid export is associated with steatosis in AKI-induced remote liver injury.Scientific reports · 2026Article
- ER Stress-Mediated Impairment of Hepatic Lipid Export Drives Steatosis in AKI-Induced Remote Liver Injury.Research square · 2026Article
- Impact of folic acid supplementation on ischemia‒reperfusion-induced kidney injury in rats: folic acid prophylactic role revisited.The journal of physiological sciences : JPS · 2024Article
- Delayed graft function post renal transplantation: a review on animal models and therapeutics.American journal of physiology. Renal physiology · 2023Review
- Role of Iberin as an anti-apoptotic agent on renal ischemia-reperfusion injury in rats.Journal of medicine and life · 2023Article
- Acute Kidney Injury Induces Oxidative Stress and Hepatic Lipid Accumulation through AMPK Signaling Pathway.Antioxidants (Basel, Switzerland) · 2023Article
- Literature review of the mechanisms of acute kidney injury secondary to acute liver injury.World journal of nephrology · 2022Review
- The Effect of Thyme Essential Oil on Liver Injuries Caused by Renal Ischemia-Reperfusion in Rats.BioMed research international · 2022Article
- The xenobiotic receptors PXR and CAR in liver physiology, an update.Biochimica et biophysica acta. Molecular basis of disease · 2021Review
- Kidney Ischemia-Reperfusion Decreases Hydrogen Sulfide and Increases Oxidative Stress in the Heart.Biomolecules · 2020Article
- Constitutive Androstane Receptor: A Peripheral and a Neurovascular Stress or Environmental Sensor.Cells · 2020Review
- Inhibition of Estrogen Sulfotransferase (Journal of the American Society of Nephrology : JASN · 2020Article
- Kidney-secreted erythropoietin lowers lipidemia via activating JAK2-STAT5 signaling in adipose tissue.EBioMedicine · 2019Article
- Identification of Modulators That Activate the Constitutive Androstane Receptor From the Tox21 10K Compound Library.Toxicological sciences : an official journal of the Society of Toxicology · 2019Article
- The Roles of Xenobiotic Receptors: Beyond Chemical Disposition.Drug metabolism and disposition: the biological fate of chemicals · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
You-Jin ChoiCenter for Pharmacogenetics and Department of Pharmaceutical Sciences (Y.-J.C., A.C.S.B., Y.N, M.X., S.R., W.X.), Department of Pathology, School of Medicine (D.Z., Y.L.), Center for Clinical Pharmaceutical Sciences, Department of Pharmacy and Therapeutics, School of Pharmacy (T.D.N), and Department of Pharmacology and Chemical Biology (W.X.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Pharmacology, Shantou University Medical College, Shantou, Guangdong, China (Y.N.); and Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (X.G.).
Dong ZhouCenter for Pharmacogenetics and Department of Pharmaceutical Sciences (Y.-J.C., A.C.S.B., Y.N, M.X., S.R., W.X.), Department of Pathology, School of Medicine (D.Z., Y.L.), Center for Clinical Pharmaceutical Sciences, Department of Pharmacy and Therapeutics, School of Pharmacy (T.D.N), and Department of Pharmacology and Chemical Biology (W.X.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Pharmacology, Shantou University Medical College, Shantou, Guangdong, China (Y.N.); and Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (X.G.).
Anne Caroline S BarbosaCenter for Pharmacogenetics and Department of Pharmaceutical Sciences (Y.-J.C., A.C.S.B., Y.N, M.X., S.R., W.X.), Department of Pathology, School of Medicine (D.Z., Y.L.), Center for Clinical Pharmaceutical Sciences, Department of Pharmacy and Therapeutics, School of Pharmacy (T.D.N), and Department of Pharmacology and Chemical Biology (W.X.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Pharmacology, Shantou University Medical College, Shantou, Guangdong, China (Y.N.); and Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (X.G.).
Yongdong NiuCenter for Pharmacogenetics and Department of Pharmaceutical Sciences (Y.-J.C., A.C.S.B., Y.N, M.X., S.R., W.X.), Department of Pathology, School of Medicine (D.Z., Y.L.), Center for Clinical Pharmaceutical Sciences, Department of Pharmacy and Therapeutics, School of Pharmacy (T.D.N), and Department of Pharmacology and Chemical Biology (W.X.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Pharmacology, Shantou University Medical College, Shantou, Guangdong, China (Y.N.); and Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (X.G.).
Xiudong GuanCenter for Pharmacogenetics and Department of Pharmaceutical Sciences (Y.-J.C., A.C.S.B., Y.N, M.X., S.R., W.X.), Department of Pathology, School of Medicine (D.Z., Y.L.), Center for Clinical Pharmaceutical Sciences, Department of Pharmacy and Therapeutics, School of Pharmacy (T.D.N), and Department of Pharmacology and Chemical Biology (W.X.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Pharmacology, Shantou University Medical College, Shantou, Guangdong, China (Y.N.); and Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (X.G.).
Meishu XuCenter for Pharmacogenetics and Department of Pharmaceutical Sciences (Y.-J.C., A.C.S.B., Y.N, M.X., S.R., W.X.), Department of Pathology, School of Medicine (D.Z., Y.L.), Center for Clinical Pharmaceutical Sciences, Department of Pharmacy and Therapeutics, School of Pharmacy (T.D.N), and Department of Pharmacology and Chemical Biology (W.X.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Pharmacology, Shantou University Medical College, Shantou, Guangdong, China (Y.N.); and Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (X.G.).
Songrong RenCenter for Pharmacogenetics and Department of Pharmaceutical Sciences (Y.-J.C., A.C.S.B., Y.N, M.X., S.R., W.X.), Department of Pathology, School of Medicine (D.Z., Y.L.), Center for Clinical Pharmaceutical Sciences, Department of Pharmacy and Therapeutics, School of Pharmacy (T.D.N), and Department of Pharmacology and Chemical Biology (W.X.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Pharmacology, Shantou University Medical College, Shantou, Guangdong, China (Y.N.); and Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (X.G.).
Thomas D NolinCenter for Pharmacogenetics and Department of Pharmaceutical Sciences (Y.-J.C., A.C.S.B., Y.N, M.X., S.R., W.X.), Department of Pathology, School of Medicine (D.Z., Y.L.), Center for Clinical Pharmaceutical Sciences, Department of Pharmacy and Therapeutics, School of Pharmacy (T.D.N), and Department of Pharmacology and Chemical Biology (W.X.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Pharmacology, Shantou University Medical College, Shantou, Guangdong, China (Y.N.); and Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (X.G.).
Youhua LiuCenter for Pharmacogenetics and Department of Pharmaceutical Sciences (Y.-J.C., A.C.S.B., Y.N, M.X., S.R., W.X.), Department of Pathology, School of Medicine (D.Z., Y.L.), Center for Clinical Pharmaceutical Sciences, Department of Pharmacy and Therapeutics, School of Pharmacy (T.D.N), and Department of Pharmacology and Chemical Biology (W.X.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Pharmacology, Shantou University Medical College, Shantou, Guangdong, China (Y.N.); and Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (X.G.).
Wen XieCenter for Pharmacogenetics and Department of Pharmaceutical Sciences (Y.-J.C., A.C.S.B., Y.N, M.X., S.R., W.X.), Department of Pathology, School of Medicine (D.Z., Y.L.), Center for Clinical Pharmaceutical Sciences, Department of Pharmacy and Therapeutics, School of Pharmacy (T.D.N), and Department of Pharmacology and Chemical Biology (W.X.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Pharmacology, Shantou University Medical College, Shantou, Guangdong, China (Y.N.); and Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (X.G.) wex6@pitt.edu.
Beijing Tian Tan Hospital · CNCapital Medical University · CNShantou University Medical College · CNUniversity of Pittsburgh · US
Funding
The AHR-FGF221 Axis in Hepatic Steatosis and Metobolic SyndromeR01DK083952 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI XIE, WEN · 2010 to 2019
$3.0MA Novel Regulation of the Phase II Enzyme Estrogen SulfotransferaseR01ES023438 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI XIE, WEN · 2014 to 2018
$1.7MCentral role of fibroblasts in kidney repair and disease after AKIR01DK106049 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LIU, YOUHUA · 2015 to 2018
$1.4MNIDDK NIH HHS R01 DK083952NIDDK NIH HHS R01 DK106049NIEHS NIH HHS R01 ES023438
Abstract
Acute kidney injury (AKI) is associate with high mortality. Despite evidence of AKI-induced distant organ injury, a relationship between AKI and liver injury has not been clearly established. The goal of this study is to investigate whether renal ischemia-reperfusion (IR) can affect liver pathophysiology. We showed that renal IR in mice induced fatty liver and compromised liver function through the downregulation of constitutive androstane receptor (CAR; -90.4%) and inhibition of hepatic very-low-density lipoprotein triglyceride (VLDL-TG) secretion (-28.4%). Treatment of mice with the CAR agonist 1,4-bis[2-(3,5 dichloropyridyloxy)] benzene (TCPOBOP) prevented the development of AKI-induced fatty liver and liver injury, which was associated with the attenuation of AKI-induced inhibition of VLDL-TG secretion. The hepatoprotective effect of TCPOBOP was abolished in CAR
Indexed as
Acute Kidney InjuryAnimalsConstitutive Androstane ReceptorDown-RegulationFatty LiverGene Expression Regulation, NeoplasticInterleukin-6Lipoproteins, VLDLLiverLiver Function TestsMicePyridinesReceptors, Cytoplasmic and NuclearReperfusion Injury1,4-bis(2-(3,5-dichloropyridyloxy))benzeneConstitutive Androstane ReceptorInterleukin-6interleukin-6, mouseLipoproteins, VLDLPyridinesReceptors, Cytoplasmic and Nuclear
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.